Genotypic Analysis of Drug-Resistant HIV Cost-Effective
WESTPORT, Conn-Genotypic analysis of drug-resistant HIV strains appears to be cost-effective.
A new study conducted by Milton C. Weinstein, MD, from the Harvard School of Public Health, used an HIV simulation model to incorporate data from several HIV-related trials to analyze the cost-effectiveness of genotypic resistance testing. HIV-infected subjects with baseline CD4 counts of 250 cells per microliter were the target group.
Researchers found that testing following antiretroviral failure increased life expectancy by 3 months and cost $17,900 per quality-adjusted-life-year (QALY) gained. The figure for primary resistance testing was $22,300 with 20% prevalence of primary resistance, but increased to $69,000 when prevalence was assumed to be only 4%.
The cost per QALY gained never exceeded $25,000 when effectiveness, multiple cost factors, quality-of-life weights, and discount rates were varied.
Information from www.hivandhepatitis.com
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
